Verismo Therapeutics has received fast track designation from the US Food and Drug Administration (FDA) for its investigational new drug, SynKIR-110.

The investigational drug has been developed for treating patients with mesothelioma, a rare type of cancer that impacts abdominal cavities or the chest lining.

Fast-track designation is intended to help accelerate the review of drugs intended to treat serious or life-threatening conditions and address unmet medical needs.

Clinical programs which are granted this designation may also apply for accelerated approval and priority review, subject to meeting relevant criteria.

Verismo Therapeutics CEO, DMD and co-founder Dr Bryan Kim said: “We are thrilled to receive Fast Track designation from the FDA.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“This designation is an important milestone in our efforts to bring this potentially life-saving drug to patients who are in need of new treatment options.”

SynKIR-110 is an investigational drug to treat serious diseases and life-threatening conditions, specifically mesothelin-expressing mesothelioma, ovarian cancer and cholangiocarcinoma.

The new designation has been awarded to Verismo Therapeutics around seven months after it received orphan drug designation (ODD) from the US FDA for SynKIR-110 cell therapy.

Currently, Verismo Therapeutics is carrying out a Phase I multi-centre clinical trial to assess the anti-tumour activity, safety and feasibility of this investigational new drug.

The company is leveraging its novel KIR-CAR technology, a dual-chain CAR-T cell therapy, to develop new treatments for life-threatening medical conditions.